Acumen Pharmaceuticals (ABOS) closed at $0.19 on November 18, 2026, down 15.5% from the previous close, on volume of 3,018,175 shares (30-day average 5,004,608).
Data as of November 18, 2026.
ABOS Slides After ALTITUDE-AD Misses Both Primary and Key Secondary Endpoints
Market Chameleon (Mon, 2-Nov 5:28 AM ET)
Globe Newswire (Fri, 30-Oct 7:00 AM ET)
Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
Globe Newswire (Mon, 26-Oct 7:00 AM ET)
Globe Newswire (Thu, 22-Oct 7:30 AM ET)
Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026
Globe Newswire (Mon, 19-Oct 4:00 PM ET)
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
Globe Newswire (Thu, 10-Sep 4:00 PM ET)
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 2-Sep 4:00 PM ET)
ABOS Secures $35.75 Million to Propel Brain Delivery Breakthroughs in Alzheimer's Research
Market Chameleon (Mon, 16-Mar 3:06 AM ET)
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
Acumen Pharmaceuticals trades on the NASDAQ stock market under the symbol ABOS.
As of November 19, 2026, ABOS stock price declined to $0.19 with 37,774 million shares trading.
ABOS has a beta of 3.46, meaning it tends to be more sensitive to market movements. ABOS has a correlation of 0.03 to the broad based SPY ETF.
ABOS has a market cap of $13.74 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ABOS traded as high as $5.09 and as low as $.19.
The top ETF exchange traded funds that ABOS belongs to (by Net Assets): IWM, VTI, VXF, IWN, VTWO.
ABOS has underperformed the market in the last year with a price return of -88.6% while the SPY ETF gained +12.7%. ABOS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -93.1% and -12.2%, respectively, while the SPY returned -3.8% and -4.0%, respectively.
ABOS support price is $.18 and resistance is $.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABOS shares will trade within this expected range on the day.